Sponsored Content

Blue Helix Health to present NAD+ mitochondrial research at Copenhagen longevity conference

"BluNADBooster represents a next-generation approach—one that strengthens the body’s ability to generate and maintain healthy NAD+ levels while addressing the underlying mechanisms that cause NAD+ to decline with age," said Dr Mathias Ziegler, MD, PhD, Professor of Biomedicine at the University of Bergen and Chief Scientific Officer of Blue Helix Health.

Conference presentation

Norwegian biotech Blue Helix Health will present at the international "NAD for Health: Opportunities and Challenges" conference (23–25 March), where researchers from Harvard, UC Berkeley, and the Mayo Clinic will convene to examine both the promise and limitations of NAD+ science in healthy ageing.

Dr Mathias Ziegler, Professor of Biomedicine at the University of Bergen and Chief Scientific Officer of Blue Helix Health, will both present and moderate at the Copenhagen conference. His research focuses on mitochondrial NAD balance, a critical and contested area of ageing biology.

Clinical trial findings

At the heart of the company’s position is *BluNADBooster*, its flagship ingredient, which was evaluated in a randomised, double-blind, placebo-controlled clinical trial published in December 2025.

The study, involving 140 healthy ageing adults, found that *BluNADBooster* raised NAD+ levels by 26.48%—outperforming *nicotinamide riboside* (NR), which increased NAD+ levels by 22.69%. The ingredient also reduced *CD38* activity by nearly 18%, targeting one of the primary biological drivers of age-related NAD+ decline.

Functional outcomes extended beyond biochemistry, including improvements in mitochondrial efficiency, inflammatory markers (*TNF-α*, *IL-6*, *GDF-15*), cognitive performance, and physical endurance.

Market impact

"The market has been waiting for an NAD+ solution that goes beyond precursors alone," said Eric Anderson, Managing Director at NXT USA, Blue Helix’s exclusive US distribution partner.

Read More